IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail No. EV452772686US

Application of: Srivastava et al.

Confirmation No.:

1802

Serial No.:

09/873,403

Art Unit:

1642

Filed:

June 4, 2001

Examiner: Christopher H. Yaen

Attorney Docket No:

8449-178-999

For:

COMPLEXES OF ALPHA (2)

MACROGLOBULIN AND ANTIGENIC MOLECULES FOR IMMUNOTHERAPY

SUPPLEMENTAL AMENDMENT AND RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT UNDER 37 C.F.R. § 1.121(h)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response to the Notice of Non-Compliant Amendment dated April 21, 2004 and as a supplement to the Amendment under 37 C.F.R. § 1.114 filed April 5, 2004 (the "April 5, 2004 Amendment") in connection with the above-identified application, please enter the following corrected listing of all the claims and consider the following remarks. This supplemental Amendment includes the section of the April 5, 2004 Amendment that requires correction, i.e., the Listing of the Claims, and an Amendment to the Specification. Applicants submit concurrently herewith: (1) a Petition for Extension of Time for a period of one month; (2) a Revocation and Power of Attorney, executed by Michael F. Newborg, Executive Director of University of Connecticut Health Center; (3) Transmittal of Substitute Sequence Listing; (4) a sequence listing in paper format and CD-ROM; and (5) a return copy of the Notice of Non-Compliant amendment.

Amendments to the Specification begin on page 2 of this paper (doubleunderlining indicates additions; single-underlining indicates text which was underlined in the specification prior to this amendment).

Corrected Listing of the Claims begins on page 3 of this paper (singleunderlining indicates additions and strikethrough indicates deletions).

Remarks begin on page 6 of this paper.